21.08.2023 15:15:07 - dpa-AFX: GNW-Adhoc: Renovaro BioSciences Congratulates GEDi Cube on Appointment of its Chief Medical Officer
LOS ANGELES, Aug. 21, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RENB).
Renovaro BioSciences congratulates GEDi Cube on its appointment of Dr. Lester
Russell as Chief Medical Officer. For more information:
(https://gedicube.com/news (https://gedicube.com/news/gedicube-appoints-dr-
lester-russell-as-chief-medical-officer)).
"We are excited about the appointment of Dr. Russell," said Dr. Mark Dybul, CEO
of Renovaro BioSciences. "As a seasoned expert in clinical medicine and digital
health, he could enhance the capabilities of GEDi Cube to make a difference in
the lives of people at risk of or suffering from serious illnesses."
Renovaro BioSciences announced an exclusive, binding letter of intent with GEDi
Cube on August 9, 2023. (https://renovarobio.com/news/news-details/2023/AI-
Company-GEDi-Cube-International-and-Renovaro-Biosciences-Announce-a-Binding-
Exclusive-Letter-of-Intent-to-Merge-Accelerating-Fight-Against-
Cancer/default.aspx)
FORWARD-LOOKING STATEMENT
Statements in this press release that are not strictly historical in nature are
forward-looking statements. These statements are only predictions based on
current information and expectations and involve a number of risks and
uncertainties, including but not limited to the success or efficacy of our
pipeline. All statements other than historical facts are forward-looking
statements, which can be identified by the use of forward-looking terminology
such as "believes," "plans," "expects," "aims," "intends," "potential," or
similar expressions. All forward-looking statements are based on assumptions or
judgments about future events and economic conditions that may or may not be
correct or necessarily take place and that are, by their nature, subject to
significant risks, uncertainties, and contingencies. These forward-looking
statements include but are not limited to, statements regarding the Renovaro-
GEDi Cube transaction and Renovaro's plans and expectations with respect to the
potential transaction. Actual events or results may differ materially from those
projected in any of such statements due to various uncertainties, including as
set forth in Renovaro BioSciences Inc. (NASDAQ: RENB) most recent Annual Report
on Form 10-K filed with the SEC, as well as whether: Renovaro and GEDi Cube will
enter into an agreement as to the definitive terms of the transaction; a
condition to consummating the transaction may not be satisfied; Renovaro may be
unable to obtain approval to list on the Nasdaq Capital Market the shares of
Renovaro common stock expected to be issued pursuant to the transaction; the
closing of the transaction might be delayed or not occur at all. Readers are
cautioned not to place undue reliance on these forward-looking statements, which
speak only as of the date hereof. All forward-looking statements are qualified
in their entirety by this cautionary statement, and Renovaro Biosciences, Inc.
undertakes no obligation to revise or update this shareholder letter to reflect
events or circumstances after the date hereof.
Source: Renovaro Biosciences Inc.
Â